Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y384] to PI3 Kinase p110 beta
- Suitable for: WB, Flow Cyt, IP
- Knockout validated
- Reacts with: Human
Product nameAnti-PI3 Kinase p110 beta antibody [Y384]
See all PI3 Kinase p110 beta primary antibodies
DescriptionRabbit monoclonal [Y384] to PI3 Kinase p110 beta
Specificityab32569 recognises PI3-Kinases (PI3-Ks).
Tested applicationsSuitable for: WB, Flow Cyt, IPmore details
Unsuitable for: ICC or IHC
Species reactivityReacts with: Human
Predicted to work with: Guinea pig, Cow, Cat, Dog, Pig
Synthetic peptide within Human PI3 Kinase p110 beta. The exact sequence is proprietary.
- Jurkat whole cell lysate (ab7899).
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
Our Abpromise guarantee covers the use of ab32569 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500. Detects a band of approximately 110 kDa (predicted molecular weight: 123 kDa).|
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionPhosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2.
Tissue specificityExpressed ubiquitously.
PathwayPhospholipid metabolism; phosphatidylinositol phosphate biosynthesis.
Sequence similaritiesBelongs to the PI3/PI4-kinase family.
Contains 1 PI3K/PI4K domain.
- Information by UniProt
- 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta antibody
- 5-bisphosphate 3-kinase catalytic subunit beta isoform antibody
- DKFZp779K1237 antibody
Lane 1: Wild-type HAP1 cell lysate (40 µg)
Lane 2: PI3 Kinase p110 beta knockout HAP1 cell lysate (40 µg)
Lane 3: Jurkat cell lysate (40 µg)
Lane 4: K562 cell lysate (40 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab32569 observed at 125 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab32569 was shown to recognize PI3 Kinase p110 beta when PI3 Kinase p110 beta knockout samples were used, along with additional cross-reactive bands. Wild-type and PI3 Kinase p110 beta knockout samples were subjected to SDS-PAGE. Ab32569 and ab8245 (loading control to GAPDH) were diluted at 1/500 and 1/10,000 dilution respectively and incubated overnight at 4C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
Anti-PI3 Kinase p110 beta antibody [Y384] (ab32569) at 1/500 dilution + Jurkat cell lysate
Predicted band size: 123 kDa
Observed band size: 110 kDa why is the actual band size different from the predicted?
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab32569 has been referenced in 14 publications.
- Romeo V et al. Effects of PI3K Inhibition on Afucosylated Antibody-Driven Fc?RIIIa Events and Phospho-S6 Activity in NK Cells. J Immunol 203:137-147 (2019). PubMed: 31092639
- Li P et al. Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. Med Sci Monit 24:623-635 (2018). PubMed: 29384143
- Yang Y et al. Microarray pathway analysis indicated that mitogen-activated protein kinase/extracellular signal-regulated kinase and insulin growth factor 1 signaling pathways were inhibited by small interfering RNA against AT-rich interactive domain 1A in endometrial cancer. Oncol Lett 15:1829-1838 (2018). PubMed: 29399196
- Si F et al. MicroRNA-138 suppresses cell proliferation in laryngeal squamous cell carcinoma via inhibiting EZH2 and PI3K/AKT signaling. Exp Ther Med 14:1967-1974 (2017). PubMed: 28962111
- Wang H et al. Diallyl trisulfide induces osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K/Akt pathway. Oncol Rep 35:3648-58 (2016). PubMed: 27035545